Exact Sciences Analyst Ratings
Scotiabank Initiates Exact Sciences at Sector Outperform With $70 Price Target
Exact Sciences Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Aerovate Therapeutics (AVTE), Exact Sciences (EXAS)
Piper Sandler Keeps Their Buy Rating on Exact Sciences (EXAS)
Analysts Offer Insights on Healthcare Companies: Certara (CERT), Exact Sciences (EXAS) and AbCellera Biologics (ABCL)
Exact Sciences Analyst Ratings
Analysts' Top Healthcare Picks: US Physical Therapy (USPH), Exact Sciences (EXAS)
Buy Rating Affirmed for Exact Sciences on Strong Performance and Promising Growth Initiatives
Buy Rating Affirmed for Exact Sciences Amidst Strong Growth and Innovative Pipeline
Buy Rating Affirmed for Exact Sciences on Promising Multi-Cancer Detection Technology
Exact Sciences Analyst Ratings
Citigroup Maintains Buy on Exact Sciences, Announces $100 Price Target
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Geron (GERN)
Buy Rating Affirmed for Exact Sciences Amid Market Expansion and Product Advancement Prospects
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Arcellx Inc (ACLX) and Exact Sciences (EXAS)
Exact Sciences (EXAS) Receives a Buy From BTIG
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Exact Sciences (EXAS) and Springworks Therapeutics (SWTX)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Exact Sciences (EXAS), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS)
Exact Sciences Analyst Ratings